当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Cabazitaxel in Metastatic Prostate Cancer. Reply.
The New England Journal of Medicine ( IF 74.699 ) Pub Date : 2020-03-26 , DOI: 10.1056/nejmc2000990
Ronald de Wit,Johann de Bono,Daniel Castellano

This article has no abstract; the first 100 words appear below. To the Editor: In the CARD trial reported by de Wit et al. (Dec. 26 issue),1 255 patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and who had disease progression while receiving abiraterone or enzalutamide were randomly assigned to cabazitaxel or the other androgen-signaling–targeted inhibitor. Cabazitaxel significantly improved several clinical outcomes, including imaging-based progression-free survival and overall survival, as compared with hormonal treatment. This trial represents an important step forward in the understanding of appropriate advanced treatment in patients with metastatic castration-resistant prostate cancer. However, it should be noted that 61.2% of the patients received hormonal treatment . . .
更新日期:2020-03-26

 

全部期刊列表>>
材料学研究精选
Springer Nature Live 产业与创新线上学术论坛
胸腔和胸部成像专题
自然科研论文编辑服务
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
杨超勇
周一歌
华东师范大学
南京工业大学
清华大学
中科大
唐勇
跟Nature、Science文章学绘图
隐藏1h前已浏览文章
中洪博元
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
x-mol收录
福州大学
南京大学
王杰
左智伟
湖南大学
清华大学
吴杰
赵延川
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug